Clinical Value of Long Noncoding RNA ZEB1 Anti-sense1 in Cancer Patients: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Aug 7

PMID 32756112

Citations 1

Authors

Sixiang Cheng

Shengyu Guo

Hairong He

Atipatsa Chiwanda Kaminga

Huilan Xu

Affiliations

Soon will be listed here.

Abstract

Background: The high expression of long noncoding RNA ZEB1 anti-sense1 (ZEB1-AS1) has been reported in several types of cancer. However, most studies investigating this phenomenon were either case reports or used small patient samples. The objective of this meta-analysis was to clarify the potential clinical values of ZEB1-AS1 in various cancers.

Materials And Methods: The PubMed-MEDLINE, Web of Science, and EMBASE databases were searched, using systematic search terms, to find relevant research reports on this subject. The combined hazards ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated to explore the association between ZEB1-AS1 expression and overall survival (OS). The combined odd ratios (ORs) were calculated to evaluate the association between ZEB1-AS1 expression and pathological parameters. Data analysis was conducted in R software version 3.4.2. and Stata version 12.0 (College Station, TX: Stata Corp LP).

Results: Ten studies including 963 cancer patients were selected as suitable for this study. The pooled hazards ratio (HR) indicated that high ZEB1-AS1 expression was strongly associated with poor OS (pooled HR = 2.26, 95% CI: 1.80-2.85, P < .0001) in the Chinese cancer patients. Also, a high expression of ZEB1-AS1 was related to metastasis (pooled HR = 3.38, 95% CI: 1.91-6.00, P < .0001), and advanced tumor stage (pooled HR = 0.48, 95% CI: 0.29-0.81, P = .005). The up-regulation of ZEB1-AS1 was not significantly associated with histological differentiation (P = .39), sex (P = .001), and age (P = .372) of cancer patients.

Conclusion: The high expression of ZEB1-AS1 significantly predicted poor OS, poor metastasis, and high tumor stage in cancer patients, demonstrating that high ZEB1-AS1 expression may serve as a biomarker of poor prognosis in the Chinese cancer patients.

Citing Articles

Navigating the genomic instability mine field of osteosarcoma to better understand implications of non-coding RNAs.

Fatema K, Larson Z, Barrott J Biocell. 2022; 46(10):2177-2193.

PMID: 35755302 PMC: 9224338. DOI: 10.32604/biocell.2022.020141.

References

Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G . Young age and pathological features predict breast cancer outcome - report from a dual Institution experience in Serbia. J BUON. 2016; 20(6):1407-13. View

Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z . Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2015; 35(12):1575-84. DOI: 10.1038/onc.2015.223. View

Koch L . Functional genomics: Screening for lncRNA function. Nat Rev Genet. 2017; 18(2):70. DOI: 10.1038/nrg.2016.168. View

Chew H, Wun T, Harvey D, Zhou H, White R . Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4):458-64. DOI: 10.1001/archinte.166.4.458. View

Li Y, Wen X, Wang L, Sun X, Ma H, Fu Z . LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer. Surg Oncol. 2017; 26(4):527-534. DOI: 10.1016/j.suronc.2017.09.008. View

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

Liu C, Lin J . Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1. Am J Transl Res. 2016; 8(10):4095-4105. PMC: 5095304. View

Gong H, Wen H, Zhu X, Lian Y, Yang X, Qian Z . High expression of long non-coding RNA ZEB1-AS1 promotes colorectal cancer cell proliferation partially by suppressing p15 expression. Tumour Biol. 2017; 39(6):1010428317705336. DOI: 10.1177/1010428317705336. View

Iorga R, Bratu O, Marcu R, Constantin T, Mischianu D, Socea B . Venous thromboembolism in cancer patients: Still looking for answers. Exp Ther Med. 2019; 18(6):5026-5032. PMC: 6895781. DOI: 10.3892/etm.2019.8019. View

10.

Lv Q, Hu L, Chen S, Sun B, Fu M, Qin C . A Long Noncoding RNA ZEB1-AS1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma. Int J Mol Sci. 2016; 17(9). PMC: 5037710. DOI: 10.3390/ijms17091431. View

11.

Wang Q, Zhang R, Liu D . Long non-coding RNA ZEB1-AS1 indicates poor prognosis and promotes melanoma progression through targeting miR-1224-5p. Exp Ther Med. 2019; 17(1):857-862. PMC: 6307420. DOI: 10.3892/etm.2018.7005. View

12.

Cook D, Sackett D, Spitzer W . Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol. 1995; 48(1):167-71. DOI: 10.1016/0895-4356(94)00172-m. View

13.

Lin J, Zhan Y, Liu Y, Chen Z, Liang J, Li W . Increased expression of ZEB1-AS1 correlates with higher histopathological grade and promotes tumorigenesis in bladder cancer. Oncotarget. 2017; 8(15):24202-24212. PMC: 5421840. DOI: 10.18632/oncotarget.15527. View

14.

Huang E, Wang X, Roy Choudhury K, McShane L, Gonen M, Ye J . Meta-analysis of the technical performance of an imaging procedure: guidelines and statistical methodology. Stat Methods Med Res. 2014; 24(1):141-74. PMC: 5226954. DOI: 10.1177/0962280214537394. View

15.

Zhang L, Zhang L, Guo X, Zhang D, Yang F, Fan Y . Downregulation of miR-335-5p by Long Noncoding RNA ZEB1-AS1 in Gastric Cancer Promotes Tumor Proliferation and Invasion. DNA Cell Biol. 2017; 37(1):46-52. DOI: 10.1089/dna.2017.3926. View

16.

van Eeghen E, Bakker S, van Bochove A, Loffeld R . Impact of age and comorbidity on survival in colorectal cancer. J Gastrointest Oncol. 2015; 6(6):605-12. PMC: 4671847. DOI: 10.3978/j.issn.2078-6891.2015.070. View

17.

Braillon A, Bewley S . Shared Decision-Making for Cancer Screening: Visual Tools and a 4-Step Method. JAMA Intern Med. 2015; 175(11):1862. DOI: 10.1001/jamainternmed.2015.4721. View

18.

Wang Y, Bai Y, Yao W, Guo L, Wang Z . Expression of long non-coding RNA ZEB1-AS1 in esophageal squamous cell carcinoma and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 2015; 8(9):11871-6. PMC: 4637758. View

19.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

20.

Sorensen H, Mellemkjaer L, Olsen J, Baron J . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-50. DOI: 10.1056/NEJM200012213432504. View